Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

(Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Merck & Co. Inc. closed $34.98 below its 52-week high ($134.63), which the company achieved on June 25th.

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (c), Merck & Co., ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...